The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Essential Thrombocythemia (ET) patients at high-risk of thrombosis require cytoreductive treatment, typically with hydroxycarbamide. Many patients are resistant or intolerant to hydroxycarbamide (HC-RES/INT) and are at increased risk of disease progression. MAJIC-ET is a randomized phase 2 study com...

Full description

Bibliographic Details
Main Authors: O'Sullivan, JM, Hamblin, A, Yap, C, Fox, S, Boucher, R, Panchal A, Alimam, S, Dreau, H, Howard, K, Ware, P, Cross, NCP, McMullin, MF, Harrison, CN, Mead, AJ
Format: Journal article
Language:English
Published: American Society of Hematology 2019